Exciting Cancer Research from ADC Therapeutics
ADC Therapeutics is set to present significant findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The company, renowned for its advancements in antibody-drug conjugates (ADCs), has received confirmation that multiple abstracts detailing their preclinical research programs will be presented at this prestigious event.
Presentation Details
The oral presentation will focus on their groundbreaking investigation of the Claudin-6 ADC, specifically targeting ovarian and non-small cell lung cancer (NSCLC) models. With promising results that may pave the way for targeted treatment in various cancer types, this session provides a fantastic opportunity to discuss these advances.
Abstract Overview
The oral presentation boasts a title reflecting its detailed focus: "Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as a single agent or in combination in ovarian and non-small lung cancer models." Scheduled for Sunday, attendees can expect to dive deep into the research findings between 3:00 and 5:00 p.m. CT.
Poster Presentations
In addition to the oral presentation, ADC Therapeutics will showcase several poster presentations, highlighting their work on PSMA and ASCT2-targeted ADCs. These presentations are vital for sharing knowledge and collaborations in cancer treatment innovations.
Focused Studies
One significant poster will detail the preclinical development of ADCT-241, specifically targeting Prostate Cancer. Entitled "Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer," this study will take place on Wednesday from 9:00 a.m. to 12:00 p.m. CT, illustrating the company's commitment to addressing cancer treatments head-on.
Innovative Research Aims
Another inventive study at the AACR, titled "HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2," will further underline the importance ADC Therapeutics places on targeting novel ADCs that are over-expressed in a variety of cancer types. Scheduled for Monday morning, this poster aims to contribute to the ongoing dialogue on potential new cancer therapies.
About ADC Therapeutics
As a commercial-stage global leader in ADC technology, ADC Therapeutics (NYSE: ADCT) is dedicated to transforming treatment paradigms for patients with both hematologic malignancies and solid tumors. The company's commitment to innovation has already yielded tremendous success, especially with ZYNLONTA, their CD19-directed ADC that has received accelerated approval for treating relapsed or refractory diffuse large B-cell lymphoma.
The Company's Vision
ADC Therapeutics continues to push the envelope, focusing on developing new therapies that address significant unmet needs in cancer treatment. With operations based in Lausanne and additional facilities in London and New Jersey, ADC Therapeutics is well-positioned to innovate across borders.
Frequently Asked Questions
What is ADC Therapeutics working on at AACR?
ADC Therapeutics will present several preclinical studies on antibody-drug conjugates targeting Claudin-6, PSMA, and ASCT2.
What are the key focus areas in their research?
The focus revolves around treating ovarian and non-small cell lung cancer, with a vision to address various types of cancers through innovative ADCs.
When will the presentations take place?
The oral presentation is set for April 27, 2025, and various poster presentations will follow throughout the week.
What is ZYNLONTA?
ZYNLONTA is a CD19-directed antibody-drug conjugate developed by ADC Therapeutics, approved for treating lymphoma patients who have not responded to previous therapies.
How is ADC Therapeutics positioned in the market?
As a pioneer in the field of antibody-drug conjugates, ADC Therapeutics is a leading force in cancer treatment, focusing on innovative solutions with potentially transformative impacts.
